Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

BiVACOR® Total Artificial Heart Early Feasibility Study

NCT: NCT06174103 · RECRUITING

NCT IDNCT06174103
StatusRECRUITING
Start Date2024-06-26
Completion2027-03
SponsorBiVACOR Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The purpose of this study is to assess the feasibility of using the BiVACOR Total Artificial Heart (TAH) System to support adult patients with severe biventricular heart failure, or univentricular heart failure in which left ventricular assist device (LVAD) support is not recommended, who require mechanical circulatory support to sustain life. The BiVACOR TAH System is intended for use as a bridge to transplant (BTT). Feasibility will be assessed by evaluating safety and performance of the BiVACOR TAH System in study subjects.

Frequently Asked Questions

What is BiVACOR® Total Artificial Heart Early Feasibility Study?

BiVACOR® Total Artificial Heart Early Feasibility Study is a clinical trial registered under NCT06174103. Current status: RECRUITING.

What is the status of NCT06174103?

The current status of NCT06174103 (BiVACOR® Total Artificial Heart Early Feasibility Study) is: RECRUITING.

When did BiVACOR® Total Artificial Heart Early Feasibility Study start?

BiVACOR® Total Artificial Heart Early Feasibility Study started on 2024-06-26.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑